Emory University School of Medicine scientist describes fluvoxamine as a major victory for drug repurposing. The study shows approximately 90% reduction in COVID-19 related deaths among those who took it as directed in early stages of the disease, and suggests it should be adopted for those at a high risk of deterioration and unable to receive monoclonal antibodies or vaccination.